News
-
-
COMMUNIQUÉ DE PRESSE
2024 Half-Year Reviewed Condensed Consoldiated Financial Statements
-
COMMUNIQUÉ DE PRESSE
XS Financial Expands Into Middle-Market Equipment Finance, Establishing Buy-Side Capital Markets Desk
XS Financial announces strategic expansion into mid to large-ticket transactions in middle-market equipment leasing sector. Acquired by Axar and Mavik, enhancing financial strength and flexibility -
COMMUNIQUÉ DE PRESSE
LQR House Inc. Implements Strategic Cost-Cutting Measures Under Activist Investor David Lazar's Leadership
LQR House Inc. announces strategic updates including shutting down RareSips NFT platform and ending Bevage LLC partnership under new Director David Lazar to enhance operational efficiency and shareholder value -
COMMUNIQUÉ DE PRESSE
Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
Catheter Precision announces publication on non-invasive ablation technique STAR for cardiac electrophysiology. VIVO technology shows promising results in targeting heart arrhythmia areas -
COMMUNIQUÉ DE PRESSE
Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD
Inventiva annonce un abstract "late breaker" sur l'essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine lors du Liver Meeting™ 2024 organisé par l'AASLD -
COMMUNIQUÉ DE PRESSE
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Inventiva announces late breaker abstract from LEGEND Phase 2 trial evaluating lanifibranor with empagliflozin in MASH at AASLD The Liver Meeting® 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed reports 4% revenue increase in Mid-Year 2024 Financial Results with 32% decrease in loss from operations. Company highlights successful studies at ASCO and outlines strategic plan for 2025
